Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 31, 2019October 31, 2019

MC10 and University of Vermont Establish Partnership to Study Gait Impairment in Huntington’s, other Movement Disorders

News

MC10 and the University of Vermont have teamed up to advance understanding of gait impairments in Huntington’s disease and other movement disorders. The partnership will combine MC10’s BioStamp nPoint ... Read more

October 3, 2019October 3, 2019

Nmnat Enzyme May Halt Accumulation of Mutant Htt Protein Clumps in Nerve Cells, Study Shows

News

Increasing the levels of a natural enzyme called nicotinamide mononucleotide adenylyltransferase — or Nmnat — halts the formation of mutant huntingtin (Htt) protein aggregates that build up in nerves ... Read more

July 23, 2019July 23, 2019

Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition

News

EIP Pharma is launching a proof-of-concept Phase 2 clinical trial to assess the ability of therapeutic candidate neflamapimod to treat cognitive dysfunction in patients with early-stage Huntington’s disease. The ... Read more

July 18, 2019July 18, 2019

Cannabinoid Derivatives Show Therapeutic Potential in Mouse Model, But EHP-102 Still Superior

News

Emerald Health Pharmaceuticals announced that two of its cannabinoid-derived candidates — CBGA-Q and CBGA-Q-Na Salt — showed anti-inflammatory and neuroprotective effects in a mouse model of Huntington’s disease. However, ... Read more

June 4, 2019June 11, 2019

Investigational RG6042 Lowers Mutant Huntingtin Protein in Early-stage Patients, Phase 1/2 Data Show

News

RG6042, formerly called IONIS-HTTRx, a potential therapy for Huntington’s disease, was able to reduce the levels of mutant huntingtin (mHTT) protein in early-stage patients, according to results from a ... Read more

April 16, 2019April 16, 2019

Dystrogen Therapeutics’ Gene Therapy Shows Promise for Huntington’s

News

DYST 201, a gene therapy targeting the mutated forms of the gene responsible for Huntington’s disease, has shown promising results, Dystrogen Therapeutics announced. The results will be presented at two ... Read more

April 11, 2019April 11, 2019

FDA Places Gene Therapy AMT-130 on Fast Track to Speed Development

News

The U.S. Food and Drug Administration (FDA) has given fast track designation to AMT-130, uniQure’s gene therapy candidate for the treatment of Huntington’s disease. The designation helps to speed the development, testing, and ... Read more

April 4, 2019April 4, 2019

Genistein Promotes Clearance of Mutant Huntington’s Disease Protein, Study Shows

News

Genistein, a potent stimulator of cells’ natural “cleaning system” was able to reduce the levels of mutant huntingtin protein in skin cells from Huntington’s disease patients, a study has ... Read more

March 19, 2019March 19, 2019

Biomarker Platform That May Track Huntington’s Decades Before Symptom Onset Receives FDA Letter of Support

News

The U.S. Food and Drug Administration (FDA) has issued a letter of support encouraging sRNAlytics to further develop its sRNA-FIND platform for discovering and monitoring variants of small RNA molecules that ... Read more

March 12, 2019March 12, 2019

MP101 Given FDA’s Orphan Drug Status for Potential to Treat Huntington’s Disease

News

The U.S. Food and Drug Administration has granted orphan drug designation to MP101, an investigational mitochondrial-targeted neuroprotective agent, to treat Huntington’s disease. Mitochon Pharmaceuticals, the therapy’s developer, expects to begin a Phase ... Read more

Pin It on Pinterest